Regulatory Filings • Mar 31, 2018
Regulatory Filings
Open in ViewerOpens in native device viewer
RaySearch Laboratories AB (publ) has received major orders for RayStation from two radiation therapy clinics in North America. The combined order value of 6.4 MUSD (excluding service agreements), corresponding to approximately 53 MSEK, has to a large extent been delivered and is expected to generate revenue of approximately 38 MSEK in the first quarter of 2018. The remaining order value will generate revenue during the coming 15 months.
This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on March 31, 2018 at 11.30 CET.
| Johan Löf, President and CEO | Tel:: +46 8 510 530 00 |
|---|---|
| Peter Thysell, CFO | Tel: +46 70 661 0559 |
Email: [email protected] Email: [email protected]
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. In December 2017; the company launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.